Akero Therapeutics, a clinical-stage biopharmaceutical company focused on developing transformational treatments for serious metabolic and liver diseases such as metabolic dysfunction-associated steatohepatitis, priced its initial public offering of common stock at sixteen dollars per share. The public offering debuted on the Nasdaq Global Select Market under the ticker symbol AKRO. The offering successfully generated substantial gross proceeds, providing the company with vital capital to accelerate its clinical development pipelines, advance mid-stage clinical trials for its lead drug candidates, and expand its operational infrastructure.